Skip to main content
Premium Trial:

Request an Annual Quote

Affy's Acquisition of eBio Delayed Again; Firm Now Expects Deal to Close in Q1

Premium

Affymetrix this week again pushed back the date it expects to acquire eBioscience.

The Santa Clara, Calif.-based array vendor now hopes the deal will close by the end of the first quarter, citing continued work related to financing as well as a lawsuit related to the acquisition, according to a filing with the US Securities and Exchange Commission.

Affy in November announced a plan to acquire flow cytometry and immunoassay reagents provider eBioscience for $330 million in cash and debt (BAN 12/6/2011). The company originally said the deal would close by the end of 2011, but on Dec. 28 delayed the proposed acquisition to January 2012, citing financing arrangements.

A day later, TangCapital Partners, a holder of one of the company's 3.5 percent senior convertible notes due 2038, filed class action litigation in the Superior Court of California in the County of Santa Clara, alleging a number of claims, including that the acquisition would constitute a "fundamental change" under the indenture governing the notes (BAN 1/3/2012).

Tang Capital Partners is seeking "unspecified damages, temporary and permanent injunctive relief against completion of the eBioscience acquisition, and other remedies," Affy said at the time.

Further details were not disclosed.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.